Methodological Note for Switzerland

MEDA Pharma GmbH / Mylan Pharma GmbH (a Viatris Company) Turmstrasse 24 6312 Steinhausen

Viatris Pharma GmbH Turmstrasse 24 6312 Steinhausen

Pfizer PFE Switzerland GmbH (a Viatris Company) Schärenmoosstrasse 99 8052 Zürich

BGP Products Operations GmbH Turmstrasse 24 6312 Steinhausen

1. Introduction:

This Methodological Note is intended to provide information for the ethical provision of sponsorships and hospitality to Healthcare Professionals (HCP) and Healthcare Organisations (HCO) in Switzerland.

Transparency is the key to the creation of confidence in relations with the general public and patients. That is why Mylan Pharma GmbH, Viatris Pharma GmbH and BGP Products Operations GmbH are disclosing the pecuniary benefits provided between the pharmaceutical industry and stakeholders in the healthcare sector.

Kindly note that out of BGP Products Operations GmbH only interactions on a global level with Swiss HCP / Key Opinion Leaders are financed with no connection to Viatris product business in Switzerland.

The disclosure methodology follows the guidelines for reporting provided by the EFPIA Disclosure Code.

Additional information for Switzerland can be found at: scienceindustries - Disclosure obligation since 2016

2. Definitions:

Recipients

Healthcare Professional (HCP):

Any member of medical, dental, medical laboratory, pharmacy or nursing professions in Switzerland or any other similar person whose professional activities may include the recommendation, purchase, prescription, administration, use or supply of MEDA Pharma GmbH, Mylan Pharma GmbH, Viatris Pharma GmbH and Pfizer PFE Switzerland GmbH products to patients or customers.

Healthcare Institution (HCO):

Any entity, facility, institution, foundation, association, or organization employing HCPs or

otherwise affiliated with the practice of medicine by HCPs. HCOs are often end purchasers or customer accounts for MEDA Pharma GmbH, Mylan Pharma GmbH, Viatris Pharma GmbH and Pfizer PFE Switzerland GmbH products used or prescribed by HCPs. Examples of HCls include hospitals, public clinics, private clinics, and pharmacies.

Transfer of Value (ToV) categories

ToV to an HCO

Donations and Grants:

Donations and Grants to HCOs that support healthcare, including donations and grants (either cash or benefits in kind) to institutions, organisations or associations that are comprised of HCPs and/or that provide healthcare.

Contribution to costs related to Events:

Contribution to costs related to Events, through HCOs or third parties, including sponsorship to HCPs to attend Events, such as: Registration fees; Sponsorship agreements with HCOs or with third parties appointed by an HCO to manage an Event; and Travel and accommodation.

Fees for Service and Consultancy:

ToV resulting from or related to contracts between Member Companies and institutions, organisations or associations of HCPs under which such institutions, organisations or associations provide any type of services to a Member Company or any other type of funding not covered in the previous categories. Fees, on the one hand, and on the other hand ToV relating to expenses agreed in the written agreement covering the activity will be disclosed as two separate amounts.

ToV to an HCP:

Contribution to costs related to Events:

Contribution to costs related to Events, such as: Registration fees; and Travel and accommodation.

Fees for Service and Consultancy:

ToV resulting from or related to contracts between Member Companies and HCPs under which such HCPs provide any type of services to a Member Company or any other type of funding not covered in the previous categories. Fees, on the one hand, and on the other hand ToV relating to expenses agreed in the written agreement covering the activity will be disclosed as two separate amounts.

3. Disclosure Scope:

Products concerned

Products promoted, sold or distributed by MEDA Pharma GmbH, Mylan Pharma GmbH, Viatris Pharma GmbH and Pfizer PFE Switzerland GmbH, including products that are co-marketed or co-promoted, to the extent that of MEDA Pharma GmbH, Mylan Pharma GmbH, Viatris Pharma GmbH and Pfizer PFE Switzerland GmbH control the promotion of such products.

Included ToV Categories

See section 2.

Excluded ToV:

Samples; meals in connection to HCP/HCO meetings which are not part of a sponsoring ship which fall under the hospitality category; informational and educational material ToV Date Date of the ToV is the date of the effective payment. ToVs in case of partial attendance or cancellation Cancellation fees are not reported. Fees for partial attendance are disclosed.

4. Specific considerations

Individual Disclosure

ToV is disclosed on an individual basis for each clearly identifiable recipient. Indirect ToV provided to a HCP/HCO by a third party is disclosed with the HCP/HCO as recipient.

Aggregate Disclosure

ToV where certain information cannot be disclosed on an individual basis for legal reasons (f.ex. no written consent has been granted by signature) are reported in the Aggregate Disclosure Section.

Multi-year agreements

In case of a multi-year agreement the date of the effective payment in the reporting period is the date of the ToV.

5. Consent management

For disclosure on an individual basis written consent has to be obtained by HCO or HCP. HCO or HCP are free to request an aggregate disclosure. Given consent can be revoked by written request. The disclosure report will be updated in a timely manner and the ToV will be disclosed in the aggregated section.

6. Disclosure Form

Disclosures are made on an annual basis and each reporting period covers a full calendar year within 6 months after the end of the relevant Reporting Period. Disclosure platform Reports can be found for Switzerland on the local webpage:

<u>Transparenz und Datenschutz | Viatris</u>

Transparence et protection des données | Viatris

7. Disclosure of financial data

Currency

Disclosure is done in CHF for Switzerland. If payment was made in foreign currency the exchange rate of the effective day of payment was adopted.

VAT

VAT is included in all ToV disclosed for Switzerland.

 $25062024_Methodological_Note_Switzerland$